 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summaries for Patients are a service provided by Annals to help patients better understand the complicated and often mystifying language of modern medicine.
SUMMARIES FOR PATIENTS
In Some Women, Postmenopausal Hormone Use Increases Short-Term Risk for Heart Disease, but Decreases Risk in the Long Term
3 July 2001 | Volume 135 Issue 1 | Page S17
Summaries for Patients are presented for informational purposes only. These summaries are not a substitute for advice from your own medical provider. If you have questions about this material, or need medical advice about your own health or situation, please contact your physician. The summaries may be reproduced for not-for-profit educational purposes only. Any other uses must be approved by the American College of Physicians-American Society of Internal Medicine.
The summary below is from the full report titled "Postmenopausal Hormone Use and Secondary Prevention of Coronary Events in the Nurses' Health Study. A Prospective, Observational Study." It is in the 3 July 2001 issue of Annals of Internal Medicine (volume 135, pages 1-8). The authors are F Grodstein, JE Manson, and MJ Stampfer.
What is the problem and what is known about it so far?
Sorting through the potential benefits and harms of postmenopausal hormone use can be confusing. For example, established benefits include less osteoporosis (thinning of the bones) and fewer menopausal symptoms. Harms include small increases in the risk for breast and ovarian cancer. For many years, the use of postmenopausal hormones has been believed to decrease heart disease. However, a recent careful study showed that among women with known heart disease, hormone use for 1 to 3 years did not decrease repeated episodes of heart disease and did increase chances of having blood clots in the legs and lungs. However, more information is needed about the harms of taking hormones over an increasing number of years.
Why did the researchers do this particular study?
To describe how often heart disease recurs in postmenopausal women who take hormones for different lengths of time.
Who was studied?
The study included 2489 postmenopausal nurses with known coronary artery disease (narrowing of the arteries that supply blood to the heart), who were observed from 1976 to 1996. No women with stroke or cancer were studied.
How was the study done?
Every 2 years, the women answered questions about hormone use and major health problems. The researchers also reviewed the women's medical records and a national registry to identify deaths among these women and the causes of death.
What did the researchers find?
Compared with women who never took hormones, women who took hormones for less than 1 year had a 25% increase in risk for recurrent coronary heart disease. However, women who took hormones for 2 years or longer had decreased risk for recurrent heart disease. Longer duration of use was associated with lower risk. These effects of hormone use were seen after other risk factors, such as age, smoking, blood pressure, and body weight, were accounted for and regardless of whether the hormones used consisted of estrogen alone or estrogen combined with progestin.
What were the limitations of the study?
Self-reports of hormone use, as were used in this study, may not be totally accurate. More important, women who take hormones for a long time may differ in many ways from those who do not; for example, they might be more physically active or have healthier diets. It can be difficult to sort out whether the differences in heart disease that accompany postmenopausal hormone use are due to the hormones or something else.
What are the implications of the study?
Risk for recurrent coronary heart disease in postmenopausal women with known heart disease is increased with short-term (up to 1 year) use of hormones. Risk for recurrent coronary disease decreases with longer hormone use.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  V. M. Miller and S. P. Duckles Vascular Actions of Estrogens: Functional Implications Pharmacol. Rev., June 1, 2008; 60(2): 210 - 241. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Authors/Task Force Members:, G. Mancia, G. De Backer, A. Dominiczak, R. Cifkova, R. Fagard, G. Germano, G. Grassi, A. M. Heagerty, S. E. Kjeldsen, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur. Heart J., June 11, 2007; (2007) ehm236v1. [Full Text] [PDF]
|
|
|
|
 |
|
 J. E. Rossouw, R. L. Prentice, J. E. Manson, L. Wu, D. Barad, V. M. Barnabei, M. Ko, A. Z. LaCroix, K. L. Margolis, and M. L. Stefanick Postmenopausal Hormone Therapy and Risk of Cardiovascular Disease by Age and Years Since Menopause JAMA, April 4, 2007; 297(13): 1465 - 1477. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. K. Koh and B.-K. Yoon Controversies regarding hormone therapy: Insights from inflammation and hemostasis Cardiovasc Res, April 1, 2006; 70(1): 22 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Caspard, A. K Chan, and A. M Walker Determinants of the Differences in LDL-Cholesterol After Initiation of Statin Treatment Ann. Pharmacother., January 1, 2006; 40(1): 21 - 26. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. B. Petitti and D. A. Freedman Invited Commentary: How Far Can Epidemiologists Get with Statistical Adjustment? Am. J. Epidemiol., September 1, 2005; 162(5): 415 - 418. [Full Text] [PDF]
|
|
|
|
|
|
Y. T. van der Schouw and D. E. Grobbee Menopausal complaints, oestrogens, and heart disease risk: an explanation for discrepant findings on the benefits of post-menopausal hormone therapy Eur. Heart J., July 2, 2005; 26(14): 1358 - 1361. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Dick, C. Sherif, S. Sabeti, J. Amighi, E. Minar, and M. Schillinger Gender Differences in Outcome of Conservatively Treated Patients With Asymptomatic High Grade Carotid Stenosis Stroke, June 1, 2005; 36(6): 1178 - 1183. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Nguyen, D. R. Liles, P. H. Lin, and R. L. Bush Hormone Replacement Therapy and Peripheral Vascular Disease in Women Vascular and Endovascular Surgery, November 1, 2004; 38(6): 547 - 556. [Abstract] [PDF]
|
|
|
|
 |
|
 Coronary Heart Disease Obstet. Gynecol., October 1, 2004; 104(4_suppl): 41S - 48S. [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Prestwood, C. Unson, M. Kulldorff, and M. Cushman The Effect of Different Doses of Micronized 17{beta}-Estradiol on C-Reactive Protein, Interleukin-6, and Lipids in Older Women J. Gerontol. A Biol. Sci. Med. Sci., August 1, 2004; 59(8): M827 - M832. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A Lawlor, G. Davey Smith, and S. Ebrahim Commentary: The hormone replacement-coronary heart disease conundrum: is this the death of observational epidemiology? Int. J. Epidemiol., June 1, 2004; 33(3): 464 - 467. [Full Text] [PDF]
|
|
|
|
 |
|
 Canadian Task Force on Preventive Health Care Postmenopausal hormone replacement therapy for primary prevention of cardiovascular and cerebrovascular disease: Recommendation statement from the Canadian Task Force on Preventive Health Care Can. Med. Assoc. J., April 27, 2004; 170(9): 1388 - 1389. [Full Text] [PDF]
|
|
|
|
 |
|
 W. B. Kannel and D. Levy Menopause, Hormones, and Cardiovascular Vulnerability in Women Arch Intern Med, March 8, 2004; 164(5): 479 - 481. [Full Text] [PDF]
|
|
|
|
|
|
R. G. Barr, C. C. Wentowski, F. Grodstein, S. C. Somers, M. J. Stampfer, J. Schwartz, F. E. Speizer, and C. A. Camargo Jr Prospective Study of Postmenopausal Hormone Use and Newly Diagnosed Asthma and Chronic Obstructive Pulmonary Disease Arch Intern Med, February 23, 2004; 164(4): 379 - 386. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Iemolo, A. Martiniuk, D. A. Steinman, and J. D. Spence Sex Differences in Carotid Plaque and Stenosis Stroke, February 1, 2004; 35(2): 477 - 481. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. M. Newton, A. Z. LaCroix, S. R. Heckbert, L. Abraham, D. McCulloch, and W. Barlow Estrogen Therapy and Risk of Cardiovascular Events Among Women With Type 2 Diabetes Diabetes Care, October 1, 2003; 26(10): 2810 - 2816. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. E van der Elst, H. Buurma, M. L Bouvy, and A. de Boer Drug Therapy for Prevention of Recurrent Myocardial Infarction Ann. Pharmacother., October 1, 2003; 37(10): 1465 - 1477. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. P. Reiner, S. R. Heckbert, H. L. Vos, R. A. S. Ariens, R. N. Lemaitre, N. L. Smith, T. Lumley, T. D. Rea, L. A. Hindorff, G. D. Schellenbaum, et al. Genetic variants of coagulation factor XIII, postmenopausal estrogen therapy, and risk of nonfatal myocardial infarction Blood, July 1, 2003; 102(1): 25 - 30. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Grodstein, T. B. Clarkson, and J. E. Manson Understanding the Divergent Data on Postmenopausal Hormone Therapy N. Engl. J. Med., February 13, 2003; 348(7): 645 - 650. [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Herrington Hormone Replacement Therapy and Heart Disease: Replacing Dogma With Data Circulation, January 7, 2003; 107(1): 2 - 4. [Full Text] [PDF]
|
|
|
|
|
|
A. Ferrara, C. P. Quesenberry, A. J. Karter, C. W. Njoroge, A. S. Jacobson, and J. V. Selby Current Use of Unopposed Estrogen and Estrogen Plus Progestin and the Risk of Acute Myocardial Infarction Among Women With Diabetes: The Northern California Kaiser Permanente Diabetes Registry, 1995-1998 Circulation, January 7, 2003; 107(1): 43 - 48. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Radford, T. Church, F. E. Speizer, B. E. Pearson Murphy, S. R. Davis, H. G. Burger, W. H. Goodson III, H. R. Franke, I. Lev, A. Lahad, et al. Risks of Postmenopausal Hormone Replacement JAMA, December 11, 2002; 288(22): 2819 - 2824. [Full Text] [PDF]
|
|
|
|
|
|
D. A. Grimes and R. A. Lobo Perspectives on the Women's Health Initiative Trial of Hormone Replacement Therapy Obstet. Gynecol., December 1, 2002; 100(6): 1344 - 1353. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Decensi, U. Omodei, C. Robertson, B. Bonanni, A. Guerrieri-Gonzaga, F. Ramazzotto, H. Johansson, S. Mora, M. T. Sandri, M. Cazzaniga, et al. Effect of Transdermal Estradiol and Oral Conjugated Estrogen on C-Reactive Protein in Retinoid-Placebo Trial in Healthy Women Circulation, September 3, 2002; 106(10): 1224 - 1228. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. N. Butler, M. Fossel, S. M. Harman, C. B. Heward, S. J. Olshansky, T. T. Perls, D. J. Rothman, S. M. Rothman, H. R. Warner, M. D. West, et al. Is There an Antiaging Medicine? J. Gerontol. A Biol. Sci. Med. Sci., September 1, 2002; 57(9): B333 - 338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. M. Dwyer, C. K. Nordstrom, C. N. Bairey Merz, and J. H. Dwyer Carotid Wall Thickness and Years Since Bilateral Oophorectomy: The Los Angeles Atherosclerosis Study Am. J. Epidemiol., September 1, 2002; 156(5): 438 - 444. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L. Humphrey, B. K.S. Chan, and H. C. Sox Postmenopausal Hormone Replacement Therapy and the Primary Prevention of Cardiovascular Disease Ann Intern Med, August 20, 2002; 137(4): 273 - 284. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Writing Group for the Women's Health Initiative In Risks and Benefits of Estrogen Plus Progestin in Healthy Postmenopausal Women: Principal Results From the Women's Health Initiative Randomized Controlled Trial JAMA, July 17, 2002; 288(3): 321 - 333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. W. Fletcher and G. A. Colditz Failure of Estrogen Plus Progestin Therapy for Prevention JAMA, July 17, 2002; 288(3): 366 - 368. [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Herrington, E. Vittinghoff, T. D. Howard, D. A. Major, J. Owen, D. M. Reboussin, D. Bowden, V. Bittner, J. A. Simon, D. Grady, et al. Factor V Leiden, Hormone Replacement Therapy, and Risk of Venous Thromboembolic Events in Women With Coronary Disease Arterioscler. Thromb. Vasc. Biol., June 1, 2002; 22(6): 1012 - 1017. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Barrett-Connor, D. Grady, A. Sashegyi, P. W. Anderson, D. A. Cox, K. Hoszowski, P. Rautaharju, K. D. Harper, and for the MORE Investigators Raloxifene and Cardiovascular Events in Osteoporotic Postmenopausal Women: Four-Year Results From the MORE (Multiple Outcomes of Raloxifene Evaluation) Randomized Trial JAMA, February 20, 2002; 287(7): 847 - 857. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E Rossouw Hormones, genetic factors, and gender differences in cardiovascular disease Cardiovasc Res, February 15, 2002; 53(3): 550 - 557. [Full Text] [PDF]
|
|
|
|
 |
|
 J M Dixon Hormone replacement therapy and the breast BMJ, December 15, 2001; 323(7326): 1381 - 1382. [Full Text] [PDF]
|
|
|
|
|
|
M. E. Mendelsohn and R. H. Karas The Time Has Come to Stop Letting the HERS Tale Wag the Dogma Circulation, November 6, 2001; 104(19): 2256 - 2259. [Full Text] [PDF]
|
|
|
|
|
|
S. D. Fihn, S. V. Williams, J. Daley, and R. J. Gibbons Guidelines for the Management of Patients with Chronic Stable Angina: Treatment Ann Intern Med, October 16, 2001; 135(8_Part_1): 616 - 632. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D.M. Herrington Effects of oestrogen on cardiovascular events in postmenopausal women Eur. Heart J. Suppl., October 1, 2001; 3(suppl_M): M7 - M11. [Abstract] [PDF]
|
|
|
|
 |
|
 More Data Against HRT Use for Secondary Prevention Journal Watch Cardiology, August 17, 2001; 2001(817): 2 - 2. [Full Text]
|
|
|
|
|
|
K. K. Koh, W. H. Schenke, M. A. Waclawiw, G. Csako, and R. O. Cannon III Statin Attenuates Increase in C-Reactive Protein During Estrogen Replacement Therapy in Postmenopausal Women Circulation, April 2, 2002; 105(13): 1531 - 1533. [Abstract] [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article
